Therapeutic Indications

Anastrella is primarily indicated for the treatment of advanced breast cancer in postmenopausal women. Its use is specifically directed toward hormone receptor-positive cases, where the growth of the tumor is stimulated by estrogen.

Early-Stage Breast Cancer

In the context of early-stage disease, Anastrella is utilized as an adjuvant treatment. This means it is administered following primary interventions, such as surgery or radiation, to help reduce the risk of cancer recurrence in women who have undergone menopause.

Advanced and Metastatic Breast Cancer

For postmenopausal patients with advanced breast cancer, Anastrella is used to manage tumors that have spread locally or to other parts of the body. It is also indicated for patients whose disease has progressed following initial treatment with other hormonal therapies, such as tamoxifen.

Mechanism of Action and Benefits

Anastrella belongs to a class of medications known as non-steroidal aromatase inhibitors. Its primary function is to lower the levels of estrogen circulating in the body, which is a key factor in the progression of hormone-sensitive breast cancers.

Reduction of Estrogen Levels

In postmenopausal women, the primary source of estrogen is no longer the ovaries but the conversion of adrenal androgens into estrogens through the aromatase enzyme. Anastrella binds to this enzyme, significantly inhibiting the production of estrone and estradiol. By reducing the available estrogen, the medication limits the fuel source for hormone-responsive tumor cells.

Clinical Benefits

• Recurrence Risk Reduction: By suppressing estrogen production, the medication helps decrease the likelihood of the cancer returning after initial successful treatment.
• Tumor Growth Management: In advanced cases, the reduction of hormonal stimulation can help slow or stop the growth of existing tumors, contributing to disease stabilization.
• Targeted Hormonal Therapy: Because it specifically targets the aromatase enzyme, it provides a systemic treatment option tailored for hormone-dependent malignancies without the use of steroidal components.

Who Can and Cannot Use Anastrella?

Anastrella (Levonorgestrel/Ethinyl Estradiol) is officially approved for use by females of reproductive age for pregnancy prevention. Eligibility is strictly defined by regulatory authorities based on contraindications related to thromboembolic, cardiovascular, and hormone-sensitive conditions.

Populations Who Must Not Use (Contraindicated)

Official labeling mandates that Anastrella is absolutely contraindicated in females with the following conditions:

• Vascular/Thrombotic History: Current or past history of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), or cerebrovascular disease.
• Cardiovascular Risk: Uncontrolled hypertension, coronary artery disease, or thrombogenic heart valve disorders.
• Malignancy: Current or past breast cancer or other estrogen- or progestin-sensitive cancer.
• Liver Disease: Liver tumors (benign or malignant) or severe cirrhosis.
• Age and Lifestyle: Females over 35 years old who smoke.
• Pregnancy: Known or suspected pregnancy.

Age and Conditional Use

• Use is indicated only after menarche (onset of menstruation) and is not indicated after menopause.
• The medication is not recommended while breastfeeding and must not be started earlier than four weeks after delivery.

Official Interaction Restrictions and Patterns

The interaction profile for Anastrella (Ethinyl Estradiol/Levonorgestrel) is structured by documented pharmacokinetic and pharmacodynamic constraints, as outlined in official regulatory labeling.

Contraindicated Combinations and Exposure Alterations

Co-administration is formally prohibited with certain Hepatitis C combination drug regimens, such as those containing ombitasvir/paritaprevir/ritonavir pm dasabuvir, due to a documented risk of liver enzyme elevation (ALT). The use of the herbal product St. John's wort is also restricted, as its enzyme-inducing effect can significantly decrease the plasma concentration of the contraceptive hormones. Conversely, some medicines, including certain statins (e.g., Atorvastatin), may increase the systemic exposure of the estrogen component.

Metabolic and Timing Rules

Metabolic interactions are primarily driven by enzyme systems. Strong enzyme inducers, such as the antiepileptic agents Carbamazepine and Phenytoin or the anti-tuberculosis agent Rifampin, are documented to reduce the efficacy of the contraceptive by decreasing hormone levels. Conversely, Ethinyl Estradiol can act as an enzyme inhibitor, leading to increased plasma concentration of co-administered medicines such as Tizanidine. Furthermore, to mitigate drug absorption interference caused by substances like the bile acid sequestrant Colesevelam, regulatory documents require the contraceptive tablet to be administered 4 or more hours apart.

How Anastrella Works

Anastrella functions as an inhibitor of the Prolyl Hydroxylase Domain 2 (PHD2) enzyme.

Inhibition of PHD2 blocks the hydroxylation of the Hypoxia-Inducible Factor (HIF) alpha subunit, thereby promoting the stabilization of HIF alpha and preventing its rapid proteasomal degradation. Stabilized HIF alpha translocates to the nucleus where it forms a heterodimer with the HIF beta subunit.

The resulting HIF complex binds to specific hypoxia-response elements (HREs) located in the promoter regions of various target genes. This binding event initiates the transcription of these target genes, which include those responsible for iron transport and metabolism, and notably, erythropoietin (EPO). This cellular cascade regulates the systemic physiological response to low oxygen tension, culminating in increased EPO gene expression.

How to Use Anastrella: Administration Guidelines

This section details the instructions for the proper administration of Anastrella (Ethinyl Estradiol and Levonorgestrel), based on established administration protocols for contraception.

---

Administration Scope

Feature	Instruction
Route of administration	Oral. The tablet is taken by mouth.
Dosing schedule	One tablet daily at the same time every day. This is the starting and maintenance dose.
Timing in relation to meals	May be taken without regard to meals (with or without food).
Age-group rules	Not indicated for use before menarche (onset of menstruation).
Procedural conditions	Tablets must be taken in the sequence directed on the blister pack. The interval between doses must not exceed 24 hours.

---

Resulting Procedural Structure

The medicine is designed for a continuous, long-term, cyclic regimen. The administration protocol requires the user to follow specific steps:

1. Start on Schedule: Begin the first pack on either Day 1 of menses or the first Sunday following the start of menses.
2. Maintain Consistency: Take one tablet daily at the same time every day.
3. Follow Pack Order: Swallow the tablets in the sequence directed on the packaging.
4. Use Back-up (If needed): A non-hormonal back-up method must be used for the first seven consecutive days when initiating the first pack using the Sunday Start method or starting later than Day 1 of menses.
5. Continue Cycles: Start the next pack immediately after finishing the previous pack's final tablet.

The instructions establish the precise frequency, timing, and initial cycle conditions for the administration of the hormonal components, ensuring the medicine is consumed exactly as described.

Research Evidence / Overview of Studies for Anastrella

Research concerning Anastrella (Ethinyl Estradiol/Levonorgestrel) includes controlled trials, observational studies, and regulatory reviews that describe its clinical evaluation. This overview describes the structure of the available evidence base, focusing on the research questions asked, the outcomes measured, and the areas where research is still emerging.

---

Evidence for Use in Pregnancy Prevention (Contraception)

Research has primarily examined the use of this hormonal combination for fertility control. Studies in this area primarily take the form of Randomized Controlled Trials (RCTs) and large-scale observational studies. Research examined how reliably the product prevents pregnancy, often measuring outcomes using the Pearl Index (a standardized calculation of pregnancy occurrences) and the rate of ovulation inhibition in participants.

Study populations included mainly healthy adult women of reproductive age. Studies monitored measurements of pregnancy occurrence when the product was used in the controlled setting of the trials. These findings describe patterns observed in the studies and contribute to the broader evidence landscape.

---

Evidence for Managing Menstrual Symptoms

Research has also examined this combination hormonal contraceptive for its observed patterns in women experiencing certain physical symptoms associated with the menstrual cycle.

Research on Heavy Menstrual Bleeding (Menorrhagia)

The evidence for heavy menstrual bleeding (Menorrhagia) was evaluated in trials focused on women reporting heavy flow. Studies monitored outcomes such as the quantification of menstrual blood loss. Research highlights changes measured during the study period, describing a pattern related to changes in menstrual blood loss in the observed populations.

Research on Menstrual Pain (Dysmenorrhea)

Research on menstrual pain (Dysmenorrhea) was studied for outcomes related to perceived discomfort and symptom intensity. Studies conducted during periods of increased symptom activity reported changes in patient-reported pain intensity scores. Findings were sometimes mixed across studies, meaning evidence quality varies across different hormonal combinations.

---

Evidence for Managing Moderate Acne Vulgaris

This combination was studied for outcomes related to skin health in women with moderate acne vulgaris. This evidence is often derived from placebo-controlled Randomized Controlled Trials (RCTs). The studies monitored outcomes linked to inflammatory or irritative states by counting lesion numbers and using global severity assessments. Research describes a pattern of decreased lesion counts in participants compared to those receiving placebo.

---

Research Gaps and Areas of Uncertainty

The research conducted so far contributes to the broader evidence landscape, but certain limitations are consistently noted. Comparative evidence is lacking for some indications when assessing this product directly against every other treatment option. The sample sizes were modest in some non-contraceptive RCTs, and the follow-up durations were limited. Research provides context but not individual predictions; study results reflect the specific conditions under which they were conducted.

Key Studies & References ACOG Practice Bulletin No. 195: Noncontraceptive Uses of Hormonal Contraceptives (Summarizing Symptomatic Evidence)

Common questions about Anastrella (FAQ)

Q: How quickly is Anastrella supposed to start working?

A: Regulatory documents state that when initiating the first pack of this medicine, a non-hormonal back-up method of contraception is specified to be used for the first seven consecutive days. This procedural step is intended to provide contraceptive protection during the initial cycle. The prescribing information establishes a specific procedural structure for administration.

Q: What is the longest period someone typically takes Anastrella?

A: Official product information describes Anastrella as being designed for a continuous, long-term, cyclic regimen. It is typically used for as long as pregnancy prevention is desired, provided there are no changes in the user's health that would contraindicate its use. There is no predetermined maximum duration defined in the prescribing information.

Q: Can Anastrella make you feel tired or drowsy?

A: While the official product information does not explicitly list 'drowsiness,' general adverse event reports for this type of medication include symptoms such as weakness or lack of strength, sometimes called asthenia. These non-specific symptoms are reported by some users.

Q: Is Anastrella safe for older adults (seniors)?

A: Official use is strictly indicated for women of reproductive age and is not indicated after menopause. Furthermore, the medicine is formally contraindicated (use is not permitted) in women over 35 who smoke due to a documented increased risk of serious cardiovascular events. Eligibility is defined by the absence of specific contraindications, not just chronological age.

Q: Is it normal to feel slightly nauseous when first starting Anastrella?

A: Nausea and vomiting are listed as very common side effects in reports on this type of medicine. While the prescribing information notes that breakthrough bleeding or spotting may occur when first starting, nausea is a recognized adverse event.

Q: What should I do if I think I'm having a rare side effect?

A: Official patient instructions specify that users should read the patient information sheet that accompanies the drug carefully. If any new or concerning symptom, rare or common, is suspected, consultation with a healthcare provider is recommended.

Q: Do I need a special blood test before starting Anastrella?

A: Prescribing information does not universally mandate specific blood tests before the first dose. However, official guidance often recommends monitoring blood pressure, cholesterol, and/or triglycerides during the course of treatment, which typically involves testing. Determining the necessity of any initial tests is a decision made by a healthcare provider.

Q: Does Anastrella cause changes in mood or anxiety?

A: According to regulatory documents, adverse event reports include a range of psychological effects. These reported side effects can include mood changes, worsening depression, and, in some cases, anxiety or panic attacks. This information is contained within the comprehensive safety profile.

Q: Are there long-term safety studies available for Anastrella?

A: Research evidence includes various trials, but regulatory reviews often note that the follow-up durations were limited in certain studies, particularly those focused on non-contraceptive uses. The safety profile of this class of medicine is continuously monitored via post-market surveillance systems.

Q: What is the general success rate mentioned in research for Anastrella?

A: The success rate is primarily measured using the Pearl Index, which is a standardized calculation of the number of pregnancies per 100 women during one year of use. For this type of medication, with correct use, the Pearl Index is generally reported as less than 1.

Q: Are there different strengths of Anastrella?

A: While the branded product may have a standard strength, the active ingredients—ethinyl estradiol and levonorgestrel—are a combination widely available on the US market in a variety of different dosage strengths and regimen types. This means the combination is available in a variety of products.

Q: What is the maximum dose mentioned in the prescribing information?

A: The official maintenance regimen is set at one tablet daily. The regulatory label cautions against exceeding the recommended dosage and specifies that the maximum total daily dosage of the tablet's components should not be exceeded.

Q: Does Anastrella cause weight gain?

A: Weight gain or changes in appetite/weight are reported as common adverse events for this type of medication in regulatory documents. This is a recognized effect within the overall safety profile.

Q: What happens if I miss a dose of Anastrella?

A: Official patient information provides detailed instructions outlining the specific actions to be taken if an active tablet is missed. These instructions vary depending on the number of tablets missed and the timing, and often include guidance on using back-up contraception.

Q: What should I know about taking Anastrella with Tylenol or ibuprofen?

A: Regulatory documents note a possible interaction where the component ethinyl estradiol may interact with acetaminophen (Tylenol). This interaction could potentially affect the absorption or blood levels of the estrogen component. Consultation with a healthcare provider is generally necessary for co-administration guidance.

Q: How does Anastrella affect blood pressure?

A: Official warnings state that the medicine may increase blood pressure or worsen high blood pressure that is already present. Due to this risk, the drug is contraindicated (use is not permitted) in patients with uncontrolled hypertension.

Q: Are there any generic versions of Anastrella available?

A: Yes, the active ingredients in Anastrella—ethinyl estradiol and levonorgestrel—are a common combination. This combination is widely available on the US market as FDA-approved generic equivalent products through various manufacturers.

Q: Is it true that Anastrella can cause skin sensitivity to the sun?

A: The official safety information notes that this type of medicine may cause increased sensitivity to the sun. It may also lead to a condition known as chloasma, which is the formation of dark patches on the skin, particularly on the face.

Q: Can people with kidney issues use Anastrella?

A: Because the drug's components may cause fluid retention, official guidance states that patients with pre-existing conditions sensitive to fluid shifts, such as renal dysfunction (kidney issues), are candidates for close monitoring during use.

Q: Is Anastrella suitable for people with diabetes?

A: Anastrella is contraindicated (use is not permitted) in patients with diabetes who have existing vascular complications or who meet certain age and duration criteria (e.g., long duration of diabetes or over 35 years of age). Eligibility for use is determined by a comprehensive assessment of risk factors.

Q: Can Anastrella be crushed or split if it is hard to swallow?

A: Official instructions specify that users are to swallow the tablets whole and to take them in the sequence directed on the packaging. The regulatory labeling does not contain guidance that permits or instructs users to crush or split the tablets.

Q: Can I take Anastrella if I have a history of seizures?

A: The drug's components may cause fluid retention in the body. For patients with a history of epilepsy or seizures, official warnings indicate that close observation may be appropriate, as fluid shifts may potentially worsen their condition.

How to Store and Dispose of Anastrella?

The official storage and handling profile for combination hormonal contraceptive products containing levonorgestrel and ethinyl estradiol specifies strict environmental constraints to maintain product stability.

Required Storage Conditions

Condition	Requirement
Temperature	Must be stored at 20–25°C (68–77°F) (Controlled Room Temperature). Brief excursions between 15° to 30°C are permitted.
Protection	The product must be protected from light and kept from freezing.
Container	Store in a closed container; product should remain in the original blister pack.
Child Safety	Mandatory instruction to keep out of the reach of children.

Disposal Instructions

Unused or expired tablets should be managed according to specific instructions provided on the medication's labeling or by consulting a healthcare professional. Do not keep medicine that is outdated or no longer needed. Follow official government guidance for the proper disposal of unused non-flushable medication.